{"id":391692,"date":"2014-04-07T00:00:00","date_gmt":"2014-04-07T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dbason0414-biopharma-gastric-cancer-metastatic-decisionbase-us-eu-2014\/"},"modified":"2026-04-21T05:30:41","modified_gmt":"2026-04-21T05:30:41","slug":"dbason0414-biopharma-gastric-cancer-metastatic-decisionbase-us-eu-2014","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dbason0414-biopharma-gastric-cancer-metastatic-decisionbase-us-eu-2014\/","title":{"rendered":"Gastric Cancer (Metastatic) | DecisionBase | US\/EU | 2014"},"content":{"rendered":"<p><em>Treatment Choices Are Limited, but Oncologists\u2019 Receptivity to Targeted Agents Presents a Lucrative Opportunity<\/em><\/p>\n<p>The introduction of the HER2-targeting agent trastuzumab (Roche\/Genentech\/Chugai\u2019s Herceptin) in 2010 transformed the treatment algorithm for metastatic gastric cancer, segregating the population into those patients with HER2-positive disease (HER2 overexpressers) and therefore eligible for trastuzumab treatment, and those deemed HER2-negative. Despite the entrance of Herceptin, the outlook for patients with metastatic gastric cancer is bleak, notably for those with HER2-negative disease. Several emerging therapies including agents from novel drug classes are in development for metastatic gastric cancer; and owing to the high levels of unmet need, significant clinical and commercial opportunity exists for therapies that can provide greater survival benefits than current standards of care.<\/p>\n","protected":false},"template":"","class_list":["post-391692","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-gastric-cancer","biopharma-geography-us","biopharma-date-574"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391692","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391692\/revisions"}],"predecessor-version":[{"id":394815,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391692\/revisions\/394815"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391692"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}